ENGN · enGene Therapeutics Inc.
$1.79
+0.02 (+1.13%)
At close · Aug 21
Market Cap
$118.57M
Shares
66.99M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Ronald H.W. Cooper | Chief Executive Officer and President | $5,758,289 |
| Hussein Sweiti | Chief Medical Officer | $3,151,902 |
| Ryan Daws | Chief Financial Officer | $2,216,126 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Ronald H.W. Cooper | Chief Executive Officer and President | $8,433,812 |
| Lee G. Giguere | Chief Legal Officer & Secretary | $3,303,449 |
| Raj S. Pruthi | MD, MHA, FACS Chief Medical Officer | $2,466,059 |
| Jason D. Hanson | Former Chief Executive Officer | $999,299 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jason D. Hanson | Former Chief Executive Officer | $2,192,934 |
| Dr. Alexander Nichols | President and Chief Operating Officer | $969,950 |
| James Sullivan | Chief Scientific Officer | $896,242 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Jason D. Hanson | Chief Executive Officer | $649,207 |
| James Sullivan | Chief Scientific Officer | $439,866 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Dr. Richard Glickman | a director and chairman of the Board of Directors | Resigned | 2026-07-16 |
| Dr. Richard Glickman | a director and chairman of the Board of Directors | Resigned | 2026-07-16 |
| Dr. Hussein Sweiti | Chief Medical Officer and Head of Research and Development | Resigned | 2026-06-15 |
| William Grossman | director | Appointed | 2025-07-08 |
| Philip Astley-Sparke | director | Appointed | 2025-07-08 |
| Michael Heffernan | director | Appointed | 2025-07-08 |
| Jasper Bos | director of the Board of Directors | Resigned | 2025-07-08 |
| Dr. Raj S. Pruthi | Chief Medical Officer | Resigned | 2025-06-04 |
| Joan Connolly | Chief Technology Officer | Appointed | 2024-10-21 |
| Dr. Alexander Nichols | Chief Strategy and Operations Officer | Appointed | 2024-10-21 |
| Ronald H.W. Cooper | President | Appointed | 2024-10-21 |
| Dr. James Sullivan | Chief Scientific Officer | Resigned | 2024-10-21 |
| Dr. Anthony Cheung | Chief Scientific Officer | Appointed | 2024-10-21 |
| Jason D. Hanson | director | Resigned | 2024-07-24 |
| Jason D. Hanson | Chief Executive Officer | Resigned | 2024-07-24 |
| Ronald H. W. Cooper | director | Appointed | 2024-07-24 |
| Ronald H. W. Cooper | Chief Executive Officer | Appointed | 2024-07-24 |
| Lota Zoth | Director | Appointed | 2024-05-15 |
| Wouter Joustra | Director | Appointed | 2024-05-15 |
| Paul Hastings | Director | Appointed | 2024-05-15 |
| Lota Zoth | Class I Director | Appointed | 2023-12-21 |
| Ryan Daws | Chief Financial Officer and Head of Business Development | Appointed | 2023-11-29 |